WO2024171052 - ANALYTICAL METHOD
National phase entry is expected:
Publication Number
WO/2024/171052
Publication Date
22.08.2024
International Application No.
PCT/IB2024/051329
International Filing Date
13.02.2024
Title **
[English]
ANALYTICAL METHOD
[French]
PROCÉDÉ ANALYTIQUE
Applicants **
GLAXOSMITHKLINE BIOLOGICALS SA
Rue de l'Institut 89
B-1330 Rixensart, BE
CUREVAC SE
Friendrich-Miescher-Str. 15
72076 Tubingen, DE
Inventors
TOPPAZZINI, Mila
Via Fiorentina 1
53100 Siena, IT
MAGAGNOLI, Claudia
rue de l’Institut 89
B-1330 Rixensart, BE
DE RICCO, Riccardo
Via Fiorentina 1
53100 Siena, IT
FRANZINI, Roberta
Via Fiorentina 1
53100 Siena, IT
DE MARTINO, Michela
Via Fiorentina 1
53100 Siena, IT
SANTORO, Jacopo
Via Fiorentina 1
53100 Siena, IT
COCCONE, Salvatore Sanna
Via Fiorentina 1
53100 Siena, IT
CORRADO, Alessio
Via Fiorentina 1
53100 Siena, IT
IACOPINI, Dalila
Via Fiorentina 1
53100 Siena, IT
Priority Data
2302092.8
14.02.2023
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2111 | |
| EPO | Filing, Examination | 9942 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 4160 |

Total: 17375 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to liquid chromatography methods (e.g., HPLC) that facilitate high resolution separation of mRNA formulated in lipid nanoparticles (LNPs) from impurities. In aspects, the disclosure relates to a mobile phase with two or more eluents that separates constituents of a mixture into one or more peaks, wherein at least one of the peaks is a well- defined impurity peak that can be quantified to accurately determine the amount of the impurity in the mixture.[French]
La présente invention concerne des procédés de chromatographie liquide (par exemple, HPLC) qui permettent la séparation à haute résolution d'ARNm formulé dans des nanoparticules lipidiques (LNP) à partir d'impuretés. Selon certains aspects, l'invention concerne une phase mobile avec deux éluants ou plus qui sépare des constituants d'un mélange en un ou plusieurs pics, au moins l'un des pics étant un pic d'impureté bien défini qui peut être quantifié pour déterminer avec précision la quantité de l'impureté dans le mélange.